Show Stocks and Investing Publications

• Thu, January 23, 2025

by: MSN

Avidity Biosciences CFO sells $93,985 in stock

Michael F. MacLean, Chief Financial Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), recently sold shares of the company stock valued at approximately $93,985. The transactions occurred on January 21,

• Fri, January 24, 2025

by: WOPRAI

Richard Hightower Maintained (MAA) at Equal with Decreased Target to $152 on, Jan 24th, 2025

by: WOPRAI

Adam Kramer Upgraded (MAA) to Overweight and Increased Target to $168 on, Jan 24th, 2025

by: WOPRAI

Arvind Ramnani Maintained (MA) at Overweight with Increased Target to $591 on, Jan 24th, 2025

by: WOPRAI

Paul Lejuez Reinstated (KR) to Neutral and Held Target at $61 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (KHC) at Hold with Decreased Target to $32 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (ITW) at Hold with Decreased Target to $266 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (ITT) at Buy with Decreased Target to $179 on, Jan 24th, 2025

by: WOPRAI

Richard Newitter Maintained (ISRG) at Buy with Increased Target to $666 on, Jan 24th, 2025

by: WOPRAI

Joanne Wuensch Maintained (ISRG) at Buy with Increased Target to $711 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (IRT) at Equal with Decreased Target to $21 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (IR) at Hold with Decreased Target to $100 on, Jan 24th, 2025

by: WOPRAI

Julien Roch Upgraded (IPG) to Overweight and Increased Target to $36 on, Jan 24th, 2025

by: WOPRAI

Adam Kramer Downgraded (INVH) to Equal and Decreased Target to $35 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (HSY) at Hold with Decreased Target to $170 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (HAIN) at Hold with Decreased Target to $7 on, Jan 24th, 2025

by: WOPRAI

Gil Luria Maintained (GOOGL) at Neutral with Increased Target to $200 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (GIS) at Buy with Decreased Target to $72 on, Jan 24th, 2025

by: WOPRAI

Matthew Akers Maintained (GE) at Overweight with Increased Target to $250 on, Jan 24th, 2025

by: WOPRAI

Ken Herbert Maintained (GE) at Outperform with Increased Target to $220 on, Jan 24th, 2025

by: WOPRAI

Terry McEvoy Reiterated (FMBH) at Equal and Held Target at $43 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (FLS) at Buy with Increased Target to $75 on, Jan 24th, 2025

by: WOPRAI

Brian Brophy Maintained (FIX) at Buy with Increased Target to $577 on, Jan 24th, 2025

by: WOPRAI

Orest Wowkodaw Maintained (FCX) at Sector with Decreased Target to $45 on, Jan 24th, 2025

by: WOPRAI

Jay Olson Downgraded (EXEL) to Perform and Decreased Target to $33 on, Jan 24th, 2025

by: WOPRAI

Jared Shaw Maintained (EWBC) at Overweight with Decreased Target to $120 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (ESS) at Equal with Decreased Target to $302 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (EQR) at Overweight with Decreased Target to $79 on, Jan 24th, 2025

by: WOPRAI

Jeffrey Bernstein Maintained (EAT) at Equal with Increased Target to $150 on, Jan 24th, 2025

by: WOPRAI

Jeffrey Bernstein Maintained (DPZ) at Underweight with Decreased Target to $402 on, Jan 24th, 2025

by: WOPRAI

Richard Shane Maintained (DFS) at Neutral with Increased Target to $169 on, Jan 24th, 2025

by: WOPRAI

Karl Shepard Maintained (DFS) at Sector with Increased Target to $210 on, Jan 24th, 2025

by: WOPRAI

Wood Lay Maintained (CWBC) at Market with Decreased Target to $22 on, Jan 24th, 2025

by: WOPRAI

Matt Breese Reiterated (CUBI) at Equal and Held Target at $58 on, Jan 24th, 2025

by: WOPRAI

Patrick Brown Reiterated (CSX) at Outperform with Decreased Target to $37 on, Jan 24th, 2025

by: WOPRAI

James McGarragle Maintained (CSX) at Sector with Decreased Target to $33 on, Jan 24th, 2025

by: WOPRAI

Brian Ossenbeck Maintained (CSX) at Overweight with Decreased Target to $37 on, Jan 24th, 2025

by: WOPRAI

Brandon Oglenski Maintained (CSX) at Overweight with Decreased Target to $38 on, Jan 24th, 2025

by: WOPRAI

Benjamin Hartford Maintained (CSX) at Outperform with Decreased Target to $38 on, Jan 24th, 2025

by: WOPRAI

Ariel Rosa Maintained (CSX) at Buy with Decreased Target to $39 on, Jan 24th, 2025

by: WOPRAI

Nathan Jones Maintained (CR) at Hold with Decreased Target to $170 on, Jan 24th, 2025

by: WOPRAI

Richard Hightower Maintained (CPT) at Overweight with Decreased Target to $126 on, Jan 24th, 2025

by: WOPRAI

Lisa Gill Maintained (COR) at Overweight with Increased Target to $301 on, Jan 24th, 2025

by: WOPRAI

Christopher Mcgratty Maintained (COLB) at Market with Decreased Target to $33 on, Jan 24th, 2025

by: WOPRAI

Patrick Scholes Maintained (CCL) at Hold with Increased Target to $30 on, Jan 24th, 2025

by: WOPRAI

Lisa Gill Maintained (CAH) at Neutral with Increased Target to $142 on, Jan 24th, 2025

by: WOPRAI

Matthew Smith Maintained (CAG) at Hold with Decreased Target to $28 on, Jan 24th, 2025

by: WOPRAI

Matthew Akers Maintained (CACI) at Overweight with Increased Target to $536 on, Jan 24th, 2025

Avidity Biosciences CFO sells $93,985 in stock

Michael F. MacLean, Chief Financial Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), recently sold shares of the company stock valued at approximately $93,985. The transactions occurred on January 21,

The article from MSN Money discusses a recent transaction by Avidity Biosciences' Chief Financial Officer (CFO), Michael F. MacLean, who sold shares of the company's stock. On June 12, 2023, MacLean sold 12,512 shares at an average price of $7.51 per share, totaling approximately $93,985. This sale was part of a series of insider transactions at Avidity Biosciences, where insiders have been both buying and selling shares over the past year. The article provides context on insider trading, noting that while such sales can sometimes signal a lack of confidence in the company's future, they can also be for personal financial reasons unrelated to the company's performance. Avidity Biosciences, a clinical-stage biopharmaceutical company, focuses on developing treatments for rare diseases, and its stock performance and insider trading activities are often closely watched by investors for insights into the company's health and prospects.

Read the Full MSN Article at:
https://www.msn.com/en-us/money/topstocks/avidity-biosciences-cfo-sells-93-985-in-stock/ar-AA1xLaPh

Similar Stocks and Investing Publications

on: Fri, Jan 17th 2025
by: MSN

eBay CFO Stephen J. Priest sells $67,072 in company stock

Stephen J. Priest, the Senior Vice President and Chief Financial Officer of eBay Inc. (NASDAQ:EBAY), reported a recent sale of company stock. According to a Form 4 filing with the Securities and Exchange Commission,

on: Thu, Jan 16th 2025
by: MSN

JPMorgan Chase chief risk officer Ashley Bacon sells $1.81 million in stock

Ashley Bacon, Chief Risk Officer at JPMorgan Chase & Co. (NYSE:JPM), recently sold 7,122 shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The shares were sold at an average price of $253.

on: Tue, Jan 21st 2025
by: MSN

Monday's Insider Activity: Quiet Day with No Significant Trades

No significant insider purchases were reported for Monday, January 20, 2025. Top Sells: No significant insider sales were reported for Monday, January 20, 2025. Investors should s

on: Fri, Jan 17th 2025
by: MSN

Mackenzie Realty Capital CEO Robert Dixon buys $66,750 in stock

Robert E. Dixon, CEO and President of MacKenzie Realty Capital, Inc. (OTC:MKZR), recently acquired a significant number of shares in the company. According to a recent SEC filing, Dixon purchased a total of 25,

on: Wed, Dec 18th 2024
by: Motley Fool Australia

2 ASX growth shares set to skyrocket in the next 12 months

Looking for ASX growth shares that could outperform the market in 2025? Here are two ideas that could be strong market-beaters.

on: Thu, Dec 12th 2024
by: MSN

ASX 200 stock slips on $482 million retail deal

The ASX 200 stock is expanding its retail holdings by almost half a billion dollars. The post ASX 200 stock slips on $482 million retail deal appeared first on The Motley Fool Australia.

on: Thu, Dec 12th 2024
by: MSN

Here are the top 10 ASX 200 shares today

The ASX made it three losses in a row this Thursday. The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

on: Wed, Dec 11th 2024
by: MSN

IRCTC, Tata Elxsi, Adani Total Gas, AEL: Can these bruised blue chip stocks mirror Suzlon Energy's stock rebound?

The list included IRCTC, Adani Total Gas Ltd, Adani Enterprises Ltd, Gujarat Gas, SBI Card and Tata Exlsi. Others in the list included Avenue Supermarts (DMart), Berger Paints and Asian Paints.

on: Fri, Dec 06th 2024
by: Business Insider

Oriental Rise Holdings Ltd trading resumes

on: Wed, Dec 04th 2024
by: Thomas Matters

This ASX healthcare stock is up 160% in a month! Here's why it's just entered a trading halt

The company requested the pause before the open. The post This ASX healthcare stock is up 160% in a month! Here's why it's just entered a trading halt appeared first on The Motley Fool Australia.

on: Tue, Dec 03rd 2024
by: Thomas Matters

Nifty's next move: What Reliance and HDFC Bank are signalling

The Nifty50 chart is showing early signs of a potential reversal, and when we connect the dots with large-cap stocks like Reliance and HDFC Bank, the outlook becomes even more intriguing.

on: Wed, Jan 22nd 2025
by: Indiatimes

Stock Market Highlights : Nifty closes above 23,100; hammer pattern signals bullish momentum ahead. How to trade on Thursday

Indian equity markets ended positively, with the Nifty closing above 23,100 despite intraday volatility. The index rebounded strongly, forming a hammer candlestick pattern, indicating strong buying at lower levels and potential bullish momentum.